Survey Results Add to Information About ECP Treatment for CTCL

by U.S. Medicine

January 4, 2018

LEBANON, NH — Extracorporeal photopheresis (ECP) is a leukapheresis-based therapeutic procedure that has been approved by the Food and Drug Administration (FDA) for the treatment of advanced cutaneous T-cell lymphoma (CTCL) since 1988.

In ECP, white blood cells are collected and exposed to a photosensitizer, 8-methoxypsoralen (8-MOP), and ultraviolet A (UVA) radiation. UVA activates 8-MOP and causes crosslinkage of DNA. Performed via intravenous access, the procedure has three stages: (1) leukapheresis, (2) photoactivation, and (3) reinfusion of treated cell product back to the patient.

ECP, also known as extracorporeal photochemotherapy and extracorporeal photoimmunotherapy, is performed at over 200 centers worldwide. A study in the Journal of Clinical Apheresis pointed out, however, that although many apheresis centers offer ECP, little is known about current treatment practices.1

A study team led by Dartmouth-Hitchcock Medical Center researchers and including participation from the Minneapolis VAMC sought to remedy that by distributing an electronic survey to assess ECP practice internationally.

Of 251 responses, 137 met criteria for analysis. The article reports that most, 80%, of respondents were from North America. Survey responses indicated that nurses perform ECP at most centers (84%) and the majority of centers treat adults only (52%). In addition, most centers treat fewer than 50 patients/year (83%) and perform fewer than 300 procedures/year (70%).

Closed system devices (XTS and/or Cellex) are used to perform ECP at nearly all centers, 96%. Closed systems integrate drug photoactivation and reinfusion, thus lowering risk of infection, contamination, and errors during reinfusion. 

The most common indications for ECP are acute/chronic skin graft versus host disease (89%) and CTCL (63%), with a typical wait time of less than two weeks. Most centers, 66%, reported that they do not routinely perform quality control assessment of the collected product. 

The report also discussed device-specific differences in treatment parameters. “For example, XTS users more frequently have a minimum weight limit (P = 0.003) and use laboratory parameters to determine eligibility for treatment (P = 0.03),” study authors wrote. “Regardless of device used, the majority of centers assess the clinical status of the patient before each procedure.” They noted that more than 50% of respondents said they would defer treatment for hemodynamic instability due to active sepsis or heart failure, positive blood culture in the past 24 hours or current fever.

“This survey based study describes current ECP practices. Further research to provide evidence for optimal standardization of patient qualifications, procedure parameters and product quality assessment is recommended,” the researchers add.

In addition to CTCL and graft versus host disease, ECP has been shown to have efficacy in the treatment of solid organ transplant rejection, scleroderma, atopic dermatitis, epidermolysis bullosa acquisita, lichen planus, lupus erythematosus, pemphigus vulgaris, Crohn disease, and type 1 diabetes. Some researcher has suggested value of extracorporeal photopheresis in the treatment of psoriasis, rheumatoid arthritis, multiple sclerosis, nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy, and scleromyxedema. 

  1. Dunbar NM, Raval JS, Johnson A, Abikoff CM, et. al. Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee. J Clin Apher. 2017 Aug;32(4):215-223. doi: 10.1002/jca.21486. Epub 2016 Jul 21. PubMed PMID: 27442906.

Comments are closed here.


Related Articles

Racial Disparities Found in BRCA Testing, Counseling

DURHAM, NC—Despite increases in BRCA mutation testing, racial/ethnic disparities in counseling and testing have persisted for decades, a study argued. The review published in the Journal of Racial and Ethnic Health Disparities said its purpose... View Article

VA Guideline Addresses Dental Management of Head/Neck Cancer Patients

SAN FRANCISCO—Few protocols have been published for the dental management of patients with head and neck cancer to prevent complications from head and neck radiation therapy, according to a new study.  The report in the... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Racial Disparities Found in BRCA Testing, Counseling

DURHAM, NC—Despite increases in BRCA mutation testing, racial/ethnic disparities in counseling and testing have persisted for decades, a study argued. The review published in the Journal of Racial and Ethnic Health Disparities said its purpose... View Article

Oncology

VA Guideline Addresses Dental Management of Head/Neck Cancer Patients

SAN FRANCISCO—Few protocols have been published for the dental management of patients with head and neck cancer to prevent complications from head and neck radiation therapy, according to a new study.  The report in the... View Article

Oncology

Patients Treated with Thiopurines Have Higher Skin Cancer Mortality

PHILADELPHIA—Treatment with thiopurines is associated with an increased risk of squamous cell carcinoma of the skin in patients with inflammatory bowel diseases. An article in Clinical Gastroenterology and Hepatology discussed results of a study that... View Article

Oncology

Overcoming Radiation Resistant Prostate Cancer

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article

Oncology

JAK Enzymes Can Treat Leukemia, Lymphoma

NASHVILLE, TN—Precision oncology prescribes the use of molecularly-targeted therapy directed by identification of genomic alterations. A new study suggested the approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, such as... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up